↑ 薬物リストへ　← 戻る

Pilocarpine    (DrugBank: Pilocarpine)

3 diseases
告示番号疾患名（ページ内リンク）臨床試験数
6パーキンソン病2
53シェーグレン症候群5
299嚢胞性線維症2

6. パーキンソン病　［臨床試験数：2,123，薬物数：2,046（DrugBank：324），標的遺伝子数：183，標的パスウェイ数：198］
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-jRCTs041180018
04/09/201720/12/2018Pupillary autonomic dysfunction and visual hallucination in Parkinson's diseaseAssociation between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease - Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease Parkinson's disease and related diseasesTwo drops of 0.05% pilocarpine hydrochloride, which is a parasympathomimetic agent, on the right eye, 2 drops of 0.04% dipivefrin hydrochloride, which is a sympathomimetic agent, to the left eyekatsuno MasahisaNULLRecruiting>= 40age oldNot applicableBoth40Phase 2Japan
2JPRN-UMIN000026128
2017/04/0101/04/2017Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease Parkinson's diseaseadministe pilocarpine and dipivefrine
administe pilocarpine and dipivefrine		Nagoya UniversityNULLRecruiting40years-old90years-oldMale and Female60Not selectedJapan

53. シェーグレン症候群　［臨床試験数：234，薬物数：270（DrugBank：85），標的遺伝子数：49，標的パスウェイ数：174］
Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 234 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-UMIN000010796
2013/06/0124/05/2013Impact of CYP2A6 and CHRM3 genetic polymorphisms on the PK/PD of pilocarpine in Japanese healthy volunteers Sjogren's syndromesingle oral administration of pilocarpine.
salagen (KISSEI PHARMACEUTICAL CO.,LTD.)
5mg 1Tablet.		Oita University Faculty of MedicineNULLPending20years-oldNot applicableMale and Female30Not applicableJapan
2JPRN-UMIN000029307
2009/02/0127/09/2017Efficacy and safety of pilocarpine / sodium alginate formulation for dry mouth in Sjogren's syndrome patients Sjogren's syndromePilocarpine / sodium alginate solution (0.32 mL, pilocarpine 0.96 mg) is administered intra-orally 3 times a day for 7 days.Teikyo UniversityNULLComplete: follow-up complete16years-oldNot applicableMale and Female50Not selectedJapan
3JPRN-UMIN000001460
2008/10/0129/10/2008The efficacy and safety of pirocarpine hydrochloride for juvenile Sjogren's syndrome Sjogren's syndromeOral pilocarpine hydrochloride for 4 weeks.Department of Pediatrics, Graduate School of Medicine, Chiba UniverityNULLComplete: follow-up complete6years-old16years-oldMale and Female10Not selectedJapan
4NCT00438048
(ClinicalTrials.gov)		November 200620/2/2007A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy TreatmentXerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial SalivaPrimary Sjogren;Secondary Sjogren;XerostomiaProcedure: pilocarpine;Drug: Artificial SalivaPontificia Universidad Catolica de ChileFormulario MAgistral Farmacias AhumadaCompleted18 YearsN/ABoth76Phase 4Chile
5NCT04470479
(ClinicalTrials.gov)		March 1, 20057/7/2020Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens SyndromeOral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens SyndromeDry EyeDrug: Pilocarpine Hydrochloride;Drug: PlaceboFederal University of São PauloNULLCompleted18 Years65 YearsAll32Phase 3Brazil

先頭へ


299. 嚢胞性線維症　［臨床試験数：1,592，薬物数：1,539（DrugBank：255），標的遺伝子数：81，標的パスウェイ数：162］
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,592 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03584841
(ClinicalTrials.gov)		March 31, 201727/5/2018Implementation of a Non-invasive Version of the Imaging ß-adrenergic-dependent Sweat Secretion TestImplementation of a Non-invasive Version of the Imaging ß-adrenergic-dependent Sweat Secretion Test: Value for Diagnosis and Efficacy of Target Therapies for Cystic FibrosisMucoviscidosis Involving the LungDiagnostic Test: Iontophoresis sessions in forearm of subjects with pilocarpineCliniques universitaires Saint-Luc- Université Catholique de LouvainNULLRecruiting18 Years100 YearsAll120N/ABelgium
2NCT02310789
(ClinicalTrials.gov)		July 31, 20153/9/2014(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?(Study: Vertex IIS) A Study To Access the Effects of Ivacaftor on Wild Type CFTR-Open Probability (PO) In The Sweat Gland Secretory CoilCystic FibrosisDrug: Ivacaftor;Drug: ß-Adrenergic cocktail;Drug: Pilocarpine Nitrate 5%;Device: Macroduct sweat stimulatorRichard Barry MossNULLCompleted18 YearsN/AAll8N/AUnited States

先頭へ